Sirna Therapeutics is a biotechnology company exploring the use of RNA interference in human disease therapy.
Business Model:
Revenue: $0
Employees: 51-200
Sirna Therapeutics was acquired by
Merck.
The acquisition happend on 2006-10-30.
Details of the transaction were not public
Address:
City: San Francisco
State: California
Zip:
Country: United States
The scientific community considers RNA interference the breakthrough biological discovery of the decade with the potential to change how diseases are treated. Sirna Therapeutics is at the forefront of the effort to create RNAi- based therapies and leverage the vast potential of this technology to ultimately treat patients.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/8/2006
Ticker Symbol:
RNAI
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2003 | Venture Round | 6 | $48M |
Sprout Group Oxford Bioscience Partners GGV Capital Techno Venture Management Venrock Granite Ventures Sprout Group Oxford Bioscience Partners GGV Capital Techno Venture Management Venrock Granite Ventures |
7/2005 | Venture Round | $28M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|